Details

Autor(en) / Beteiligte

• Hutchinson, Peter J
• Edlmann, Ellie
• Hanrahan, John G
• Bulters, Diederik
• Zolnourian, Ardalan
• Holton, Patrick
• Suttner, Nigel
• Agyemang, Kevin
• Thomson, Simon
• Anderson, Ian A
• Al-Tamimi, Yahia
• Henderson, Duncan
• Whitfield, Peter
• Gherle, Monica
• Brennan, Paul M
• Allison, Annabel
• Thelin, Eric P
• Tarantino, Silvia
• Pantaleo, Beatrice
• Caldwell, Karen
• Davis-Wilkie, Carol
• Mee, Harry
• Warburton, Elizabeth A
• Barton, Garry
• Chari, Aswin
• Marcus, Hani J
• Pyne, Sarah
• King, Andrew T
• Belli, Antonio
• Myint, Phyo K
• Wilkinson, Ian
• Santarius, Thomas
• Turner, Carole
• Bond, Simon
• Kolias, Angelos G

Titel

A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)

Ist Teil von

• Health technology assessment (Winchester, England), 2024-03, Vol.28 (12), p.1-122

Ort / Verlag

England: NIHR Journals Library

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Chronic subdural haematoma is a collection of 'old blood' and its breakdown products in the subdural space and predominantly affects older people. Surgical evacuation remains the mainstay in the management of symptomatic cases. The Dex-CSDH (DEXamethasone in Chronic SubDural Haematoma) randomised trial investigated the clinical effectiveness and cost-effectiveness of dexamethasone in patients with a symptomatic chronic subdural haematoma. This was a parallel, superiority, multicentre, pragmatic, randomised controlled trial. Assigned treatment was administered in a double-blind fashion. Outcome assessors were also blinded to treatment allocation. Neurosurgical units in the UK. Eligible participants included adults (aged ≥ 18 years) admitted to a neurosurgical unit with a symptomatic chronic subdural haematoma confirmed on cranial imaging. Participants were randomly assigned in a 1 : 1 allocation to a 2-week tapering course of dexamethasone or placebo alongside standard care. The primary outcome was the Modified Rankin Scale score at 6 months dichotomised to a favourable (score of 0-3) or an unfavourable (score of 4-6) outcome. Secondary outcomes included the Modified Rankin Scale score at discharge and 3 months; number of chronic subdural haematoma-related surgical interventions undertaken during the index and subsequent admissions; Barthel Index and EuroQol 5-Dimension 5-Level utility index score reported at discharge, 3 months and 6 months; Glasgow Coma Scale score reported at discharge and 6 months; mortality at 30 days and 6 months; length of stay; discharge destination; and adverse events. An economic evaluation was also undertaken, during which the net monetary benefit was estimated at a willingness-to-pay threshold of £20,000 per quality-adjusted life-year. A total of 748 patients were included after randomisation: 375 were assigned to dexamethasone and 373 were assigned to placebo. The mean age of the patients was 74 years and 94% underwent evacuation of their chronic subdural haematoma during the trial period. A total of 680 patients (91%) had 6-month primary outcome data available for analysis: 339 in the placebo arm and 341 in the dexamethasone arm. On a modified intention-to-treat analysis of the full study population, there was an absolute reduction in the proportion of favourable outcomes of 6.4% (95% confidence interval 11.4% to 1.4%; = 0.01) in the dexamethasone arm compared with the control arm at 6 months. At 3 months, the between-group difference was also in favour of placebo (-8.2%, 95% confidence interval -13.3% to -3.1%). Serious adverse events occurred in 60 out of 375 (16.0%) in the dexamethasone arm and 24 out of 373 (6.4%) in the placebo arm. The net monetary benefit of dexamethasone compared with placebo was estimated to be -£97.19. This trial reports a higher rate of unfavourable outcomes at 6 months, and a higher rate of serious adverse events, in the dexamethasone arm than in the placebo arm. Dexamethasone was also not estimated to be cost-effective. Therefore, dexamethasone cannot be recommended for the treatment of chronic subdural haematoma in this population group. A total of 94% of individuals underwent surgery, meaning that this trial does not fully define the role of dexamethasone in conservatively managed haematomas, which is a potential area for future study. This trial is registered as ISRCTN80782810. This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 13/15/02) and is published in full in ; Vol. 28, No. 12. See the NIHR Funding and Awards website for further award information.